These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 23486421)

  • 1. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
    Nester CM; Brophy PD
    Curr Opin Pediatr; 2013 Apr; 25(2):225-31. PubMed ID: 23486421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome.
    Westra D; Wetzels JF; Volokhina EB; van den Heuvel LP; van de Kar NC
    Neth J Med; 2012 Apr; 70(3):121-9. PubMed ID: 22516576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome.
    Walsh PR; Johnson S
    Pediatr Nephrol; 2019 Sep; 34(9):1485-1492. PubMed ID: 30058046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.
    Wehling C; Amon O; Bommer M; Hoppe B; Kentouche K; Schalk G; Weimer R; Wiesener M; Hohenstein B; Tönshoff B; Büscher R; Fehrenbach H; Gök ÖN; Kirschfink M
    Clin Exp Immunol; 2017 Feb; 187(2):304-315. PubMed ID: 27784126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.
    Mallett A; Hughes P; Szer J; Tuckfield A; Van Eps C; Cambell SB; Hawley C; Burke J; Kausman J; Hewitt I; Parnham A; Ford S; Isbel N
    Intern Med J; 2015 Oct; 45(10):1054-65. PubMed ID: 26247170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.
    Fakhouri F; Frémeaux-Bacchi V; Loirat C
    Eur J Intern Med; 2013 Sep; 24(6):492-5. PubMed ID: 23756030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study.
    Monet-Didailler C; Chevallier A; Godron-Dubrasquet A; Allard L; Delmas Y; Contin-Bordes C; Brissaud O; Llanas B; Harambat J
    Nephrol Dial Transplant; 2020 Dec; 35(12):2147-2153. PubMed ID: 31411695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-complement therapy for glomerular diseases.
    Bomback AS
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):152-8. PubMed ID: 24602464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.
    Zuber J; Fakhouri F; Roumenina LT; Loirat C; Frémeaux-Bacchi V;
    Nat Rev Nephrol; 2012 Nov; 8(11):643-57. PubMed ID: 23026949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.
    Zimmerhackl LB; Hofer J; Cortina G; Mark W; Würzner R; Jungraithmayr TC; Khursigara G; Kliche KO; Radauer W
    N Engl J Med; 2010 May; 362(18):1746-8. PubMed ID: 20445192
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.
    Okumi M; Tanabe K
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():9-13. PubMed ID: 26988663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A patient with a homozygous diacylglycerol kinase epsilon (DGKE) gene mutation with atypical haemolytic uraemic syndrome and low C3 responded well to eculizumab: a case report.
    Alabdulqader M; Alfakeeh K
    BMC Nephrol; 2021 Apr; 22(1):140. PubMed ID: 33879077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
    Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T
    Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eculizumab in post-transplant C3 glomerulonephritis caused by a C3 mutation
.
    Kim JS; Foster KW; Westphal SG
    Clin Nephrol; 2020 Jan; 93(1):51-56. PubMed ID: 31661064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts.
    Burbach M; Suberbielle C; Brochériou I; Ridel C; Mesnard L; Dahan K; Rondeau E; Hertig A
    Transplantation; 2014 Nov; 98(10):1056-9. PubMed ID: 24839895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study.
    Percheron L; Gramada R; Tellier S; Salomon R; Harambat J; Llanas B; Fila M; Allain-Launay E; Lapeyraque AL; Leroy V; Adra AL; Bérard E; Bourdat-Michel G; Chehade H; Eckart P; Merieau E; Piètrement C; Sellier-Leclerc AL; Frémeaux-Bacchi V; Dimeglio C; Garnier A
    Pediatr Nephrol; 2018 Aug; 33(8):1385-1394. PubMed ID: 29572749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eculizumab in renal transplantation.
    Legendre C; Sberro-Soussan R; Zuber J; Rabant M; Loupy A; Timsit MO; Anglicheau D
    Transplant Rev (Orlando); 2013 Jul; 27(3):90-2. PubMed ID: 23747093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic complement activation and complement gene analysis in enterohaemorrhagic Escherichia coli-associated paediatric haemolytic uraemic syndrome.
    Ahlenstiel-Grunow T; Hachmeister S; Bange FC; Wehling C; Kirschfink M; Bergmann C; Pape L
    Nephrol Dial Transplant; 2016 Jul; 31(7):1114-21. PubMed ID: 27190382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of complement monoclonal antibody eculizumab in Shiga toxin producing Escherichia coli associated hemolytic uremic syndrome: A review of current evidence.
    Mahat U; Matar RB; Rotz SJ
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27913. PubMed ID: 31286658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eculizumab in secondary atypical haemolytic uraemic syndrome.
    Cavero T; Rabasco C; López A; Román E; Ávila A; Sevillano Á; Huerta A; Rojas-Rivera J; Fuentes C; Blasco M; Jarque A; García A; Mendizabal S; Gavela E; Macía M; Quintana LF; María Romera A; Borrego J; Arjona E; Espinosa M; Portolés J; Gracia-Iguacel C; González-Parra E; Aljama P; Morales E; Cao M; Rodríguez de Córdoba S; Praga M
    Nephrol Dial Transplant; 2017 Mar; 32(3):466-474. PubMed ID: 28339660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.